RU2304139C2 - Кристаллические формы vi и vii кальциевой соли аторвастатина - Google Patents

Кристаллические формы vi и vii кальциевой соли аторвастатина Download PDF

Info

Publication number
RU2304139C2
RU2304139C2 RU2004103470/04A RU2004103470A RU2304139C2 RU 2304139 C2 RU2304139 C2 RU 2304139C2 RU 2004103470/04 A RU2004103470/04 A RU 2004103470/04A RU 2004103470 A RU2004103470 A RU 2004103470A RU 2304139 C2 RU2304139 C2 RU 2304139C2
Authority
RU
Russia
Prior art keywords
reaction mixture
atorvastatin
calcium salt
mixture
water
Prior art date
Application number
RU2004103470/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2004103470A (ru
Inventor
М. Сать нара на РЕДДИ (IN)
М. Сатьянараяна РЕДДИ
Чакилам НАГАРАДЖУ (IN)
Чакилам НАГАРАДЖУ
Гудипати СРИНИВАСУЛУ (IN)
Гудипати СРИНИВАСУЛУ
Катакам СИНИВАС (IN)
Катакам СИНИВАС
Саджи м Раджесвар РЕДДИ (IN)
Саджиям Раджесвар РЕДДИ
Original Assignee
Д-р Редди'с Лабораторис Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Д-р Редди'с Лабораторис Лтд filed Critical Д-р Редди'с Лабораторис Лтд
Publication of RU2004103470A publication Critical patent/RU2004103470A/ru
Application granted granted Critical
Publication of RU2304139C2 publication Critical patent/RU2304139C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2004103470/04A 2001-07-30 2002-01-07 Кристаллические формы vi и vii кальциевой соли аторвастатина RU2304139C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN620MA2001 2001-07-30
IN620MAS/01 2001-07-30

Publications (2)

Publication Number Publication Date
RU2004103470A RU2004103470A (ru) 2005-06-20
RU2304139C2 true RU2304139C2 (ru) 2007-08-10

Family

ID=35160889

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004103470/04A RU2304139C2 (ru) 2001-07-30 2002-01-07 Кристаллические формы vi и vii кальциевой соли аторвастатина

Country Status (19)

Country Link
EP (2) EP2292600A1 (enExample)
JP (1) JP2005500351A (enExample)
KR (1) KR20040019043A (enExample)
CN (1) CN100471836C (enExample)
AU (1) AU2002255479B2 (enExample)
BG (1) BG108518A (enExample)
BR (1) BR0211488A (enExample)
CA (1) CA2454500C (enExample)
CZ (1) CZ2004126A3 (enExample)
EE (1) EE200400048A (enExample)
HR (1) HRP20040077A2 (enExample)
IL (2) IL159626A0 (enExample)
MX (1) MXPA04000889A (enExample)
NO (1) NO20040390L (enExample)
NZ (1) NZ530785A (enExample)
PL (1) PL368647A1 (enExample)
RU (1) RU2304139C2 (enExample)
WO (1) WO2003011826A1 (enExample)
ZA (1) ZA200400573B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
PL362472A1 (en) * 2000-11-03 2004-11-02 Teva Pharma Atorvastatin hemi-calcium form vii
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
KR100790766B1 (ko) * 2000-12-27 2008-01-03 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴의 결정 형태, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2003070702A1 (en) * 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
IL163594A0 (en) 2002-02-19 2005-12-18 Teva Pharma Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
CA2508871C (en) * 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
SI1727795T1 (sl) 2004-03-17 2012-05-31 Ranbaxy Lab Ltd Postopek za pripravo atorvastatin kalcija v amorfni obliki
WO2005090301A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
RU2412191C2 (ru) * 2004-07-16 2011-02-20 Лек Фармасьютиклз Д.Д. Продукты окислительной деструкции кальций аторвастатина
MX2007000765A (es) * 2004-07-20 2007-03-28 Warner Lambert Co Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1).
EP1694685A1 (en) 2004-09-28 2006-08-30 Teva Pharmaceutical Industries Ltd Process for preparing forms of atorvastatin calcium substantially free of impurities
KR20070067175A (ko) 2004-10-28 2007-06-27 워너-램버트 캄파니 엘엘씨 무정형 아토르바스타틴 형성 방법
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
MX2007014329A (es) * 2005-12-13 2008-03-19 Teva Pharma Forma cristalina de hemi-calcio de atorvastatina y procesos para la preparacion de ella.
EP2185527A2 (en) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
CN108157405B (zh) * 2018-02-06 2020-10-02 上海应用技术大学 一种灭蟑螂饵剂及其制备方法和应用
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003958A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO1997003959A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
RU2141946C1 (ru) * 1993-05-17 1999-11-27 Фудзисава Фармасьютикал Ко., Лтд. Производные гуанидина, способ их получения, способ ингибирования na+/h+ - обмена в клетках
WO2001036384A1 (en) * 1999-11-17 2001-05-25 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5929156A (en) 1997-05-02 1999-07-27 J.M. Huber Corporation Silica product for use in elastomers
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
PL362472A1 (en) * 2000-11-03 2004-11-02 Teva Pharma Atorvastatin hemi-calcium form vii
IL155890A0 (en) * 2000-11-16 2003-12-23 Teva Pharma HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
KR100790766B1 (ko) * 2000-12-27 2008-01-03 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴의 결정 형태, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2141946C1 (ru) * 1993-05-17 1999-11-27 Фудзисава Фармасьютикал Ко., Лтд. Производные гуанидина, способ их получения, способ ингибирования na+/h+ - обмена в клетках
WO1997003958A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO1997003959A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO2001036384A1 (en) * 1999-11-17 2001-05-25 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium

Also Published As

Publication number Publication date
IL159626A0 (en) 2004-06-01
CN100471836C (zh) 2009-03-25
CA2454500A1 (en) 2003-02-13
NZ530785A (en) 2005-10-28
JP2005500351A (ja) 2005-01-06
EP2292600A1 (en) 2011-03-09
RU2004103470A (ru) 2005-06-20
IL159626A (en) 2013-04-30
BR0211488A (pt) 2004-08-17
EP1414796A1 (en) 2004-05-06
WO2003011826A1 (en) 2003-02-13
HRP20040077A2 (en) 2004-06-30
MXPA04000889A (es) 2004-06-03
AU2002255479B2 (en) 2008-09-11
CA2454500C (en) 2009-11-10
BG108518A (en) 2004-08-31
KR20040019043A (ko) 2004-03-04
CZ2004126A3 (cs) 2004-12-15
ZA200400573B (en) 2005-05-11
EE200400048A (et) 2004-04-15
CN1537098A (zh) 2004-10-13
NO20040390L (no) 2004-01-29
PL368647A1 (en) 2005-04-04

Similar Documents

Publication Publication Date Title
RU2304139C2 (ru) Кристаллические формы vi и vii кальциевой соли аторвастатина
EP2192112B1 (en) Process for preparing atorvastatin hemi-calcium Form I
KR0167101B1 (ko) [r-(r*,r*)]-2-(4-플루오로페닐)-베타, 델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산, 그의 락톤형 및 염류
US6605636B2 (en) Atorvastatin hemi-calcium form VII
EP1535613B1 (en) Process for preparing a polymorphic form of atorvastatin calcium
AU2002255479A1 (en) Crystalline forms VI and VII of atorvastatin clacium
EA000474B1 (ru) Кристаллическая кислая кальциевая соль [r-(r*, r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1н-пиррол-1-гептановой кислоты (аторвастатин)
SK7212003A3 (en) Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-fenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid esters with calcium hydroxide
KR100724515B1 (ko) 아토르바스타틴 헤미칼슘의 신규한 결정형, 이의 제조 방법 및 아토르바스타틴 헤미칼슘 i형, viii형 및 ix형을 제조하는 신규한 방법
JP2006503024A (ja) Ｖｉ型アトルバスタチンカルシウムまたはその水和物
US20080287691A1 (en) Polymorphic form of atorvastatin calcium
US7074818B2 (en) Crystalline forms VI and VII of Atorvastatin calcium
KR100878140B1 (ko) 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
EP1732886B1 (en) Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin
WO2008108572A1 (en) Novel crystal forms of pyrrolylheptanoic acid derivatives
JP2008500327A (ja) アトルバスタチンの塩形態
ZA200501802B (en) Atorvastatin calcium form VI or hydrates thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130108